Druck Icon

Eckert & Ziegler awards grants to young researchers in nuclear medicine

Berlin, October 14, 2009. This year's travel grants from Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700) have been awarded to five nuclear medicine scientists from Germany, Italy, Poland and Switzerland. The prize-winners were selected by a jury from the European Association of Nuclear Medicine (EANM) from a total of 520 entries. Work in the fields of cancer diagnostics and therapy received recognition. The travel grants, which amount to 1,000 EUR each, were presented today at the annual congress of the EANM in Barcelona to:

F. Bruchertseifer, Ph.D., Germany: In vitro and in vivo comparison of 226Th- and 213Bi-labelled radioconjugates for targeted alpha therapy G. Giovacchini, Ph.D., Italy: PSA vs. PSA Doubling Time for Prediction of [11C]Choline PET/CT in Prostatectomized Prostate Cancer J. Kunikowska, Ph.D., Poland: Comparison between clinical results of PRRT with 90Y-DOTA TATE and 90Y/177Lu- DOTATATE C. Steiner, Ph.D., Switzerland: Work-up before pelvic radiotherapy treatment planning using multimodality imaging in prostate cancer: Combined SPECT/CT lymphoscintigraphy and 18F-choline PET/CT T. Wendler, Germany: Clinical introduction of freehand SPECT for image-guided sentinel lymph node biopsy

"The Positron Emission Tomography (PET) imaging technique is the fastest growing segment on the medical device market.In presenting the 'EANM Eckert & Ziegler Abstract Award' we wish to encourage young researchers to present their ideas to a wider audience and to collaborate more in exchanging ideas with other researchers engaged in the field of nuclear medicine. We hope that this will help to ensure that the enormous progress which has been made in medical imaging can soon be transformed into more precise, faster or cheaper methods of diagnosis and therapy," explained Dr. Andreas Eckert, CEO of Eckert & Ziegler.

Eckert & Ziegler AG is one of the world's largest providers of isotope component technology for radiation therapy and nuclear medicine. The Berlin based company has 520 employees and expects sales of approx. 100 Mio EUR in 2009. You can find further information about the Eckert & Ziegler travel grant at www.ezag.de/en/award_e.html.

The Board of Directors